Rubicon Research Ltd Company Summary

Rubicon Research Limited was incorporated on May 6, 1999, as a Private Limited Company under the name Rubicon Consultants Private Limited, issued by the RoC. Subsequently, the Company name was changed from Rubicon Consultants Private Limited to RubiconResearch Private Limited consequent to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Companys status converted from a Private Limited Company to a Public Limited Company, the name was changed from Rubicon Research Private Limited to Rubicon Research Limited.

A fresh Certificate of Incorporation dated July 23, 2024 was issued bythe Registrar of Companies, Central Processing Centre, Manesar, Haryana consequent to Companys conversion into a Public Limited Company.Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra.The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011.

In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte.

Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limited on slump sale as a going concern.

In 2024, the Company acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. Validus has twobrand name products in the CNS therapy area (Equetro and Marplan). The Company is planning to raise money from public through IPO aggregating to Rs 1085 Crores, consisting Rs 500 Crore Fresh Issue Equity Shares and an Offer for Sale of Rs 585 Crore Equity Shares.